iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Basis of Presentation (Policies)
Notes Tables
Notes Details

Commitments and Contingencies (Details Textual)

v2.4.1.9

Commitments and Contingencies (Details Textual) (USD $)	3 Months Ended		9 Months Ended		1 Months Ended	12 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jan. 31, 2014	Jun. 30, 2014	Dec. 30, 2013
Commitments and Contingencies [Line Items]
Research and Development Expense, Total	$ 815,000us-gaap_ResearchAndDevelopmentExpense	$ 343,000us-gaap_ResearchAndDevelopmentExpense	$ 2,731,000us-gaap_ResearchAndDevelopmentExpense	$ 1,480,000us-gaap_ResearchAndDevelopmentExpense
Contractual Obligation	3,000,000us-gaap_ContractualObligation		3,000,000us-gaap_ContractualObligation
Novici Biotech LLC [Member]
Commitments and Contingencies [Line Items]
Research and Development Expense, Total	258,000	124,000	738,000	430,000
Commitments [Member]
Commitments and Contingencies [Line Items]
Research Services Agreements Value Fulfilling Commitment			2,400,000
Termination of Research Services Agreement					1,500,000
Research and Development Expense, Total			1,500,000		500,000
Royalty Guarantees, Commitments, Amount	4,000,000		4,000,000
License Costs						30,627
Initial license fee						20,000
Contractual Obligation, Due in Next Twelve Months							78,000
Contractual Obligation, Due in Second Year							161,754
Commitments [Member] \| Minimum [Member]
Commitments and Contingencies [Line Items]
License Costs			25,000
Commitments [Member] \| Maximum [Member]
Commitments and Contingencies [Line Items]
License Costs			$ 150,000

- Details

Name:	ibio_CommitmentsAndContingenciesLineItems
Namespace Prefix:	ibio_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of initial license fee paid by the company during the reporting period.

+ References

No definition available.

+ Details

Name:	ibio_InitialLicenseFee
Namespace Prefix:	ibio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Research services agreements value fulfilling commitment during the reporting period.

+ References

No definition available.

+ Details

Name:	ibio_ResearchServicesAgreementsValueFulfillingCommitement
Namespace Prefix:	ibio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Termination of research services agreements value fulfilling commitment during the reporting period.

+ References

No definition available.

+ Details

Name:	ibio_TerminationOfResearchServicesAgreement
Namespace Prefix:	ibio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.

+ References

No definition available.

+ Details

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of contractual obligation maturing in the next fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name:	us-gaap_ContractualObligationDueInNextTwelveMonths
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of contractual obligation maturing in the second fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name:	us-gaap_ContractualObligationDueInSecondYear
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount the entity has committed to make for future royalty guarantees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 928

-SubTopic 440

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013

+ Details

Name:	us-gaap_RoyaltyGuaranteesCommitmentsAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_EligibleItemOrGroupForFairValueOptionAxis=us-gaap_CommitmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibio_NoviciBiotechLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: